Tarsus Pharmaceuticals (TARS) Other Operating Expenses (2020 - 2026)

Tarsus Pharmaceuticals' Other Operating Expenses history runs 7 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 80.31% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $34.9 million (up 112.84% YoY), while the FY2025 annual figure was $30.7 million, up 139.23% from the prior year.
• Other Operating Expenses was $9.4 million for Q1 2026 at Tarsus Pharmaceuticals, down from $10.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $10.9 million in Q4 2025 to a low of $33000.0 in Q1 2022.
• Historically, Other Operating Expenses has averaged $5.2 million across 5 years, with a median of $5.1 million in 2024.
• Biggest YoY gain for Other Operating Expenses was 41466.67% in 2022; the steepest drop was 97.46% in 2022.
• A 5-year view of Other Operating Expenses shows it stood at $9.9 million in 2022, then plunged by 87.75% to $1.2 million in 2023, then surged by 305.1% to $4.9 million in 2024, then soared by 121.82% to $10.9 million in 2025, then retreated by 14.01% to $9.4 million in 2026.
• The last three Other Operating Expenses figures came in at $9.4 million (Q1 2026), $10.9 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.